Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial.
Harrington J, Mentz RJ, Rockhold FW, Garg J, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Blackman N, Hernandez AF. Harrington J, et al. Among authors: blackman n. Am Heart J. 2023 Dec;266:25-31. doi: 10.1016/j.ahj.2023.08.005. Epub 2023 Aug 19. Am Heart J. 2023. PMID: 37598795 Clinical Trial.
Comparison of Postoperative Continuous Wireless Cardiac Rhythm Monitoring with Traditional Telemetry in Cardiac Surgery Patients: the SMART-TEL Study.
Pidoux J, Conus E, Blackman N, Orrit J, Khatchatourov G, Ruchat P, Puricel S, Cook S, Goy JJ. Pidoux J, et al. Among authors: blackman n. J Innov Card Rhythm Manag. 2024 Aug 15;15(8):5997-6003. doi: 10.19102/icrm.2024.15085. eCollection 2024 Aug. J Innov Card Rhythm Manag. 2024. PMID: 39193532 Free PMC article.
Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID.
Nouhravesh N, Garg J, Rockhold FW, De Pasquale CG, O'Meara E, Lewis GD, Butler J, Harrington J, Ezekowitz JA, Ponikowski P, Troughton RW, Wong YW, Blackman N, Numan S, Adamczyk R, Hernandez AF, Mentz RJ. Nouhravesh N, et al. Among authors: blackman n. Eur J Heart Fail. 2024 Jun 19. doi: 10.1002/ejhf.3348. Online ahead of print. Eur J Heart Fail. 2024. PMID: 38896006
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial.
Harrington J, Mentz RJ, Rockhold FW, Garg J, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Storie T, Blackman N, Hernandez AF. Harrington J, et al. Among authors: blackman n. Circ Heart Fail. 2024 Feb;17(2):e010676. doi: 10.1161/CIRCHEARTFAILURE.123.010676. Epub 2024 Jan 22. Circ Heart Fail. 2024. PMID: 38250799 Review.
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N, Hernandez AF; HEART-FID Investigators. Mentz RJ, et al. Among authors: blackman n. N Engl J Med. 2023 Sep 14;389(11):975-986. doi: 10.1056/NEJMoa2304968. Epub 2023 Aug 26. N Engl J Med. 2023. PMID: 37632463 Clinical Trial.
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD).
Makharadze T, Boccia R, Krupa A, Blackman N, Henry DH, Gilreath JA. Makharadze T, et al. Among authors: blackman n. Am J Hematol. 2021 Dec 1;96(12):1639-1646. doi: 10.1002/ajh.26376. Epub 2021 Nov 19. Am J Hematol. 2021. PMID: 34653287 Free PMC article. Clinical Trial.
75 results